Title:Understanding Alzheimer’s Disease and its Metal Chelation Therapeutics: A
Narrative Review
Volume: 29
Issue: 30
Author(s): Ritik Thakur, Ritu Karwasra and Tarana Umar*
Affiliation:
- Central Council for Research in Unani Medicine (CCRUM),
Ministry of Ayush, Government of India, Janakpuri, New Delhi 110058, India
Keywords:
Neurodegenerative diseases, Alzheimer’s diseases, neurons, metal chelation therapy, clioquinol, chelator.
Abstract: The neurodegenerative disorders are age-related illnesses that cause the morphology or activity of
neurons to deteriorate over time. Alzheimer’s disease is the most frequent neurodegenerative illness in the
long run. The rate of advancement might vary, even though it is a progressive neurological illness. Various explanations
have been proposed, however the true etiology of Alzheimer’s disease remains unclear. Most pharmacological
interventions are based on the cholinergic theory, that is earliest idea. In accordance with the amyloid
hypothesis, the buildup of beta-amyloid in brain regions is the primitive cause of illness. There is no proof
that any one strategy is useful in avoiding Alzheimer’s disease, though some epidemiological studies have
suggested links within various modifiable variables, such as cardiovascular risk, diet and so on. Different metals
like zinc, iron, and copper are naturally present in our bodies. In metal chelation therapy drugs are used to
jam the metal ions from combining with other molecules in the body. Clioquinol is one of the metal chelation
drugs used by researchers. Research on metal chelation is still ongoing. In the present review, we go over the
latest developments in prevalence, incidence, etiology, or pathophysiology of our understanding of
Alzheimer’s disease. Additionally, a brief discussion on the development of therapeutic chelating agents and
their viability as Alzheimer’s disease medication candidates is presented. We also assess the effect of clioquinol
as a potential metal chelator.
